Literature DB >> 23855493

Portal vein omentin is increased in patients with liver cirrhosis but is not associated with complications of portal hypertension.

Kristina Eisinger1, Sabrina Krautbauer, Reiner Wiest, Thomas Karrasch, Yvonne Hader, Marcus N Scherer, Stefan Farkas, Charalampos Aslanidis, Christa Buechler.   

Abstract

BACKGROUND: Omentin is a visceral fat-derived adipokine associated with endothelium-dependent vasodilation. Impaired endothelial function is a major cause of portal hypertension in liver cirrhosis. The aim was to assess associations of omentin with systemic markers of endothelial function, namely arginine and asymmetric dimethylarginine (ADMA) and complications of portal hypertension in liver cirrhosis.
MATERIALS AND METHODS: Systemic omentin was measured by ELISA in portal venous serum (PVS), systemic venous serum (SVS) and hepatic venous serum (HVS) of 40 patients with liver cirrhosis and 10 liver-healthy controls. ADMA and arginine were determined in SVS of the patients by ELISA.
RESULTS: Omentin is elevated in PVS and tends to be increased in SVS and HVS of patients with liver cirrhosis compared with controls. Omentin is principally expressed in visceral fat, and PVS omentin tends to be higher than SVS levels. Lower HVS than PVS omentin suggests that omentin may be partly removed from the circulation by the liver. Omentin in serum is not associated with stages of liver cirrhosis defined by CHILD-POUGH or MELD score and is not affected in patients with ascites. HVS omentin tends to be reduced in patients with large varices compared with patients without/with small varices. Arginine/ADMA ratio is reduced in patients with massive ascites but is not associated with variceal size. Further, Arginine/ADMA ratio does not correlate with omentin.
CONCLUSION: Current data show that PVS omentin is increased in liver cirrhosis but is not associated with complications of portal hypertension.
© 2013 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Adipokine; CHILD-POUGH stage; portal vein; varices

Mesh:

Substances:

Year:  2013        PMID: 23855493     DOI: 10.1111/eci.12122

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  11 in total

1.  Circulating fibroblast growth factor 21 in patients with liver cirrhosis.

Authors:  Sabrina Krautbauer; Lisa Rein-Fischboeck; Elisabeth M Haberl; Rebekka Pohl; Reiner Wiest; Christa Buechler
Journal:  Clin Exp Med       Date:  2017-07-25       Impact factor: 3.984

Review 2.  Alcohol, adipose tissue and liver disease: mechanistic links and clinical considerations.

Authors:  Richard Parker; Seung-Jin Kim; Bin Gao
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

Review 3.  Increased circulatory asymmetric dimethylarginine and multiple organ failure: bile duct ligation in rat as a model.

Authors:  Jiunn-Ming Sheen; Yu-Chieh Chen; You-Lin Tain; Li-Tung Huang
Journal:  Int J Mol Sci       Date:  2014-03-05       Impact factor: 5.923

4.  Omentin-1 rs2274907 and resistin rs1862513 polymorphisms influence genetic susceptibility to nonalcoholic fatty liver disease.

Authors:  Leila Kohan; Mehrnush Safarpur; Hamed Abdollahi
Journal:  Mol Biol Res Commun       Date:  2016-03

Review 5.  Omentin-A Novel Adipokine in Respiratory Diseases.

Authors:  Yan Zhou; Bo Zhang; Caixia Hao; Xiaoting Huang; Xiaohong Li; Yanhong Huang; Ziqiang Luo
Journal:  Int J Mol Sci       Date:  2017-12-28       Impact factor: 5.923

Review 6.  Adipokines in Liver Cirrhosis.

Authors:  Christa Buechler; Elisabeth M Haberl; Lisa Rein-Fischboeck; Charalampos Aslanidis
Journal:  Int J Mol Sci       Date:  2017-06-29       Impact factor: 5.923

7.  Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosis.

Authors:  Michał Kukla; Marek Waluga; Michał Żorniak; Agnieszka Berdowska; Piotr Wosiewicz; Tomasz Sawczyn; Rafał J Bułdak; Marek Ochman; Katarzyna Ziora; Tadeusz Krzemiński; Marek Hartleb
Journal:  World J Gastroenterol       Date:  2017-04-14       Impact factor: 5.742

8.  Serum omentin-1, vaspin, and apelin levels and central obesity in patients with nonalcoholic fatty liver disease.

Authors:  Farzaneh Montazerifar; Ali Reza Bakhshipour; Mansour Karajibani; Zahra Torki; Ali Reza Dashipour
Journal:  J Res Med Sci       Date:  2017-05-30       Impact factor: 1.852

9.  Changes of serum omentin-1 levels and relationship between omentin-1 and insulin resistance in chronic hepatitis C patients.

Authors:  Walaa Moustafa Hussein Nassif; Ashraf Ismail Amin; Zeinab Abdeltawab Hassan; Dalia Hussein Abdelhafiz Abdelaziz
Journal:  EXCLI J       Date:  2013-11-04       Impact factor: 4.068

10.  Serum omentin-1 levels in type 2 diabetic obese women in relation to glycemic control, insulin resistance and metabolic parameters.

Authors:  Nehal Hamdy Elsaid; Noha Adly Sadik; Nagwa Ramadan Ahmed; Sherry Elisha Fayez; Nagwa Abd El-Ghaffar Mohammed
Journal:  J Clin Transl Endocrinol       Date:  2018-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.